(Q35756756)

10 August 2017

1 reference

title

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection (English)

1 reference

10 August 2017

Horatio B Fung

1

1 reference

10 August 2017

Yi Guo

series ordinal

2

1 reference

10 August 2017

language of work or name

1 reference

1 March 2004

1 reference

10 August 2017

published in

Clinical Therapeutics

1 reference

10 August 2017

volume

26

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

352-378

1 reference

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

New antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Novel compounds in preclinical/early clinical development for the treatment of HIV infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

New anti-HIV agents and targets

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

HIV-1 cell entry and advances in viral entry inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

The potential for HIV fusion inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

1 reference

7 January 2021

The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

The plasma membrane as a combat zone in the HIV battlefield

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

HIV infection--a new drug and new costs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Enfuvirtide, a new drug for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Fusion inhibition--a major but costly step forward in the treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Destruction of primary CD4(+) T cells by cell-cell interaction in human immunodeficiency virus type 1 infection in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Nailing down another HIV target

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

Large-scale manufacture of peptide therapeutics by chemical synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990032-X

7 January 2021

10.1016/S0149-2918(04)90032-X

Identifiers

DOI

1 reference

10 August 2017

1 reference